论文部分内容阅读
选用３Ｈ－ＴｄＲ释放法及掺入法分别检测ＬＡＫ细胞活性、ＬＡＫ细胞增殖功能及９种临床常用肺癌化疗药物对ＬＡＫ细胞抗肿瘤活性的影响。结果显示，不同化疗药物对ＩＬ－２诱导ＬＡＫ细胞活性的影响不同，同种化疗药物不同浓度间的影响也有差异。卡铂（Ｃａｒｂｏ）、足叶乙甙（ＶＰ１６）、５－氟尿嘧啶（５－Ｆｕ）有增强作用；环磷酰胺（ＣＴＸ）、顺铂（ＣＤＤＰ）、长春新碱（ＶＣＲ）、甲氨喋呤（ＭＴＸ）对ＩＬ－２诱导ＬＡＫ细胞活性无明显影响；阿霉素（ＡＤＭ）、丝裂霉素（ＭＭＣ）在较高浓度时，抑制ＬＡＫ细胞活性产生。除ＣＴＸ外的８种药物均显著抑制ＬＡＫ细胞增殖功能。实验表明：常规剂量的化疗不会抑制ＬＡＫ细胞活性的产生，５－Ｆｕ、Ｃａｒｂｏ、ＶＰ１６与ＩＬ－２结合抗癌可望产生协同疗效．ＩＬ－２先于化疗给药并维持至化疗后一定时间，其联合抗癌效果可能更佳。
3H-TdR release method and incorporation method were used to detect the effects of LAK cell activity, LAK cell proliferation function and 9 clinical commonly used lung cancer chemotherapy drugs on the anti-tumor activity of LAK cells. The results showed that different chemotherapeutic agents had different effects on the activity of IL-2 induced LAK cells, and the effects of different concentrations of the same chemotherapeutic agents were also different. Enhanced effects of Carbo, VP16, and 5-Fu; cyclophosphamide (CTX), cisplatin (CDDP), vincristine (VCR), methotrexate (MTX) had no significant effect on IL-2 induced LAK cell activity; adriamycin (ADM) and mitomycin (MMC) inhibited LAK cell activity at higher concentrations. All 8 drugs except CTX significantly inhibited LAK cell proliferation. Experiments show that: conventional doses of chemotherapy will not inhibit the production of LAK cells, 5-Fu, Carbo, VP16 and IL-2 combined anti-cancer is expected to produce a synergistic effect. IL-2 is administered prior to chemotherapy and maintained for a certain period of time after chemotherapy, and its combined anti-cancer effect may be better.